Summary of Warrants Outstanding (Details) - Warrant [Member] - $ / shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2022 |
Mar. 31, 2021 |
|
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Number of Warrants, Beginning Balance | 40,000 | 640,000 |
Weighted Average Exercise Price, Beginning Balance | $ 1.00 | $ 1.00 |
Number of Warrants, Granted | ||
Weighted Average Exercise Price, Granted | ||
Number of Warrants, Exercised | ||
Weighted Average Exercise Price, Exercised | ||
Number of Warrants, Expired | ||
Weighted Average Exercise Price, Expired | ||
Number of Warrants, Ending Balance | 40,000 | 640,000 |
Weighted Average Exercise Price, Ending Balance | $ 1.00 | $ 1.00 |
X | ||||||||||
- Definition Weighted average exercise price, exercised No definition available.
|
X | ||||||||||
- Definition Weighted average exercise price, expired No definition available.
|
X | ||||||||||
- Definition Weighted average exercise price, granted No definition available.
|
X | ||||||||||
- Definition Weighted average exercise price, beginning balance No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|